Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901156 | 0.83 | HRH3 (0.62) | CHEK2CYP4F2CYP4A11EPHX2HRH3 | |
| SCHEMBL9013886 | 0.83 | CASP6 (0.53) | CHEK2CYP4F2CYP4A11NAMPTHRH3 | |
| SCHEMBL16220677 | 0.83 | EPHX2 (0.56) | CHEK2CYP4F2CYP4A11NAMPTEPHX2 | |
| SCHEMBL22196904 | 0.83 | JAK3 (0.52) | EPHX2 | |
| SCHEMBL24596887 | 0.82 | CYP4F2 (0.51) | CHEK2CYP4F2CYP4A11NAMPTEPHX2 | |
| SCHEMBL31370640 | 0.82 | ALDH1A1 (0.55) | CHEK2CYP4F2CYP4A11NAMPTHRH3 | |
| SCHEMBL2096831 | 0.82 | EPHX2 (0.55) | CHEK2CYP4F2CYP4A11NAMPTEPHX2 | |
| Hydrochloric Acid SCHEMBL9014030 | 0.82 | CASP6 (0.51) | CHEK2CYP4F2CYP4A11NAMPTHRH3 | |
| SCHEMBL5243542 | 0.81 | SRD5A1 (0.50) | EPHX2KMT2ASRD5A1 | |
| SCHEMBL2091338 | 0.81 | EPHX2 (0.57) | CYP4F2CYP4A11NAMPTEPHX2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | CHEK2 2512/4885CYP4F2 1597/4885CYP4A11 292/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | CHEK2 2512/4885CYP4F2 1597/4885CYP4A11 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.